Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

pareptide

Known as: glycinamide, L-prolyl-N-methyl-D-leucyl- 
 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

MSH Release-Inhibiting Hormone
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1987
1987
Pharmacological activities of the MIF-1 analogues Pro-Leu-Gly, Tyr-Pro-Leu-Gly and pareptide
The pharmacological activities of the related free acid analogues of MIF-1, Pro-Leu-Gly (PLG) and Tyr-Pro-Leu-Gly (YPLG), were… Expand
1984
1984
Pro-Leu-Gly-NH2 and pareptide inhibit development of tolerance to haloperidol catalepsy in the mouse
Single doses of MIF-1 (0.03-2.0 mg/kg, SC) and chronic pretreatments with MIF-1 (0.03-2.0 mg/kg, SC, BID, 3 1/2 days) or… Expand
1981
1981
Determination of the melanotropin-inhibiting factor analogue pareptide in urine by high-performance liquid chromatography.
 
1980
1980
Degradation of Melanotropin Inhibiting Factor by Brain
Degradation of melanotropin inhibiting factor (MIF) was measured by fluorometry, using pareptide as an internal standard… Expand
1979
1979
Trace analysis of the MIF analogue pareptide in blood plasma by high-performance liquid chromatography and short-wavelength excitation fluorometry.
A high-performance liquid chromatographic procedure was developed and applied to analysis of the pharmacologically active MIF… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE